ProVen VCT (LON:PVN - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 57 ($0.77) and last traded at GBX 57 ($0.77), with a volume of 27072 shares changing hands. The stock had previously closed at GBX 58.50 ($0.79).
ProVen VCT Price Performance
The company has a market cap of £159.15 million, a P/E ratio of 16.82 and a beta of 0.02. The company has a fifty day simple moving average of GBX 59.06 and a 200-day simple moving average of GBX 59.12.
ProVen VCT (LON:PVN - Get Free Report) last posted its quarterly earnings results on Monday, June 9th. The company reported GBX 0.20 ($0.00) earnings per share (EPS) for the quarter. ProVen VCT had a return on equity of 5.22% and a net margin of 67.04%.
About ProVen VCT
(
Get Free Report)
ProVen VCT plc is a venture capital trust specializing in emerging growth stage investment,expansion and management buyouts. The fund invests in small and medium sized smaller companies. It does not invest in startups. It seeks to invest in non-qualifying investments including cash, liquidity funds, fixed interest securities, debt and debt related securities in growth companies and non-qualifying venture capital investments.
Further Reading
Before you consider ProVen VCT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProVen VCT wasn't on the list.
While ProVen VCT currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access